title: Efficacy and pharmacokinetic activity of frovatriptan compared to rizatriptan in patients with moderate-to-severe migraine.
abstract: BACKGROUND
  Migraine is a painful neurological disorder that affects over 10% of the general population. Frovatriptan and rizatriptan are antimigraine agents belonging to the triptan class. Although previous studies have independently compared the efficacy of these agents, contemporaneous data examining both pharmacokinetic (PK) properties and efficacy in parallel have not previously been available.
  
  
  METHODS
  In this single-center double-blind study, 18 subjects (ten female) were treated for a single migraine attack with frovatriptan 2.5 mg or rizatriptan 10 mg. Plasma concentrations were measured predose and at 2, 4, 6, 12, 24, 48, and 72 hours after drug administration. The primary end point of this study was to evaluate the association between PK parameters and efficacy measures and recurrence rate. Secondary end points were pain-free and pain-relief episodes at 2 and 4 hours, recurrent episodes within 48 hours, and cumulative hazard of recurrence within 72 hours.
  
  
  RESULTS
  At baseline, approximately 17% of patients had mild migraine, while 83% had moderate-severe migraine. Although the time to maximum concentration was similar for both drugs (2.7 versus 2.3 hours), the terminal half-life for frovatriptan was longer than rizatriptan (29.3 versus 3.2 hours, P<0.0001). The proportion of patients who were pain-free at 4 hours without rescue medication was higher in the frovatriptan-treated group, (38.9 versus 5.6%, P=0.045). The cumulative hazard of recurrence over 72 h was reduced by frovatriptan compared to rizatriptan-treated patients (log-rank test, P=0.04). Pain-free and pain-relief episodes for the study period were positively correlated with the concentration:maximum concentration (Cmax) ratio for frovatriptan (r=0.52, P=0.028), but not rizatriptan. Recurrence rate was negatively correlated with the concentration:Cmax ratio for both frovatriptan (r=-0.96, P=0.0024) and rizatriptan (r=-0.98, P=0.0004). Fewer adverse events were observed for frovatriptan compared to rizatriptan (one versus eight, P=0.021).
  
  
  CONCLUSIONS
  This pilot study indicates that a similar extent of initial pain relief is afforded by both triptans in migraine treatment. The longer duration of action of frovatriptan parallels and correlates with its PK profile.
authors.affiliation: Department of Neuroscience, University of Turin, Turin, Italy.
authors.forename: Lidia
authors.initials: L
authors.lastname: Savi
authors.affiliation: Primula Multimedia SRL, Pisa, Italy.
authors.forename: Selene
authors.initials: S
authors.lastname: Mogavero
authors.affiliation: Primula Multimedia SRL, Pisa, Italy.
authors.forename: Colin Gerard
authors.initials: CG
authors.lastname: Egan
mesh_terms: D000328:Adult; D002227:Carbazoles / Q000009:adverse effects / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D006207:Half-Life; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy* / Q000503:physiopathology; D010865:Pilot Projects; D012008:Recurrence; D017366:Serotonin Receptor Agonists / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome; D014230:Triazoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D014363:Tryptamines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D002227:Carbazoles; D017366:Serotonin Receptor Agonists; D014230:Triazoles; D014363:Tryptamines; C093622:rizatriptan; C108128:frovatriptan
keywords: frovatriptan; headache; migraine; pain; rescue medication; rizatriptan
references.citation: Cephalalgia. 2002 Oct;22(8):633-58
references.pmid: 12383060
references.citation: Headache. 2011 Jul-Aug;51 Suppl 2:77-83
references.pmid: 21770929
references.citation: J Headache Pain. 2011 Apr;12(2):219-26
references.pmid: 20686810
references.citation: Neurology. 2012 Apr 24;78(17):1337-45
references.pmid: 22529202
references.citation: J Headache Pain. 2011 Feb;12(1):5-12
references.pmid: 20878535
references.citation: J Clin Pharmacol. 2004 Oct;44(10):1158-65
references.pmid: 15342617
references.citation: Headache. 2002 Apr;42 Suppl 2:S54-62
references.pmid: 12028321
references.citation: N Engl J Med. 2010 Jul 1;363(1):63-70
references.pmid: 20592298
references.citation: Expert Opin Pharmacother. 2008 Apr;9(6):1001-11
references.pmid: 18377342
references.citation: Cephalalgia. 2004;24 Suppl 1:9-160
references.pmid: 14979299
references.citation: Int J Clin Pract. 2004 Jul;58(7):695-705
references.pmid: 15311727
references.citation: J Clin Pharmacol. 2000 Jan;40(1):74-83
references.pmid: 10631625
references.citation: Expert Opin Pharmacother. 2003 Jan;4(1):83-93
references.pmid: 12517245
references.citation: Drug Metab Dispos. 2000 Jan;28(1):89-95
references.pmid: 10611145
references.citation: J Headache Pain. 2013 Sep 24;14:79
references.pmid: 24063537
references.citation: Neurol Sci. 2012 May;33 Suppl 1:S61-4
references.pmid: 22644173
references.citation: Headache. 2003 Apr;43(4):376-88
references.pmid: 12656709
references.citation: Drugs. 2000 Dec;60(6):1259-87
references.pmid: 11152011
references.citation: Headache. 2002 Apr;42 Suppl 2:S47-53
references.pmid: 12028320
references.citation: Headache. 2002 Apr;42 Suppl 2:S63-73
references.pmid: 12028322
references.citation: Headache. 2012 Feb;52(2):333-9
references.pmid: 22288433
references.citation: Expert Opin Pharmacother. 2006 Aug;7(11):1503-14
references.pmid: 16859433
references.citation: Neuropsychiatr Dis Treat. 2008 Feb;4(1):49-54
references.pmid: 18728819
references.citation: J Headache Pain. 2011 Jun;12(3):361-8
references.pmid: 21437714
references.citation: J Headache Pain. 2011 Dec;12(6):609-15
references.pmid: 21842274
references.citation: CNS Drugs. 2012 Sep 1;26(9):791-811
references.pmid: 22900951